Business
AIM Notice (17)
AIM Notice (17).
About this update from Immupharma Plc
[{"type":"text","content":"\n \nRNS Number : 7432G Immupharma PLC 05 March 2018 \n\n\n\n\n\n5 March 2018\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nImmuPharma PLC\n(\"ImmuPharma\" or the \"Company\")\n \nAIM Rule 17 Notice\n \nImmuPharma PLC (LSE: IMM), specialist drug discovery and development company, announces pursuant to Rule 17 of the AIM Rules for Companies (\"AIM Rules\"), the following director's disclosure under Schedule Two, Paragraph (g) of the AIM Rules:\n \nTim McCarthy, the Company's Non-executive Chairman, is currently on the board of Harvard Healthcare Limited (\"Harvard\"). On 5 March 2018 the Directors of Harvard passed a board resolution following which Harvard will be placed into a Creditors' Voluntary Liquidation. \n \nThis announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.\n \n \n \n-Ends-\n\n\n\n\nFor further information please contact:\n \n\n\n\n\nImmuPharma plc (www.immupharma.org)\n\n\n+ 44 (0) 20 7152 4080\n\n\n\n\nTim McCarthy, Chairman\n\n\n\n\n\n\n\nLisa Baderoon, Head of Investor Relations\[email protected]\nTwitter: @immupharma\n \n\n\n+ 44 (0) 7721 413496\n \n \n\n\n\n\nNorthland Capital Partners Limited (NOMAD & Broker)\nDavid Hignell, Dugald J. Carlean, Jamie Spotswood, Corporate Finance\nRob Rees, Corporate Broking\n\n\n+44 (0)20 3861 6625\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n \n\nThis information is provided by RNSThe company news service from the London Stock Exchange END AMOEAKDSEFFPEFF\n ","length":4758,"tagName":"div"}]